<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18639" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bronchiectasis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bird</surname>
            <given-names>Kim</given-names>
          </name>
          <aff>Danville Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Memon</surname>
            <given-names>Jawedulhadi</given-names>
          </name>
          <aff>King Fahad Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kim Bird declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jawedulhadi Memon declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18639.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Bronchiectasis is a chronic lung disease characterized by persistent and lifelong widening of the bronchial airways and weakening of the function mucociliary transport mechanism owing to repeated infection contributing to bacterial invasion and mucus pooling throughout the bronchial tree. This activity reviews the evaluation and management of bronchiectasis and reviews the role of the interprofessional team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of bronchiectasis.</p></list-item><list-item><p>Summarize the role of airway obstruction, infection, and peribronchial fibrosis in the pathophysiology of bronchiectasis.</p></list-item><list-item><p>Outline the evaluation of bronchiectasis.</p></list-item><list-item><p>Review the importance of collaboration and communication among the interprofessional team to enhance the delivery of care for patients with this condition.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18639&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18639">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18639.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Initially, bronchiectasis was described in the early 19th century by Laennec.&#x000a0;Bronchiectasis is a chronic lung disease characterized by&#x000a0;persistent and lifelong widening of the bronchial airways and weakening&#x000a0;of&#x000a0;the function mucociliary transport mechanism&#x000a0;owing to repeated infection contributing to bacterial invasion and mucus pooling throughout the bronchial tree.<xref ref-type="bibr" rid="article-18639.r1">[1]</xref><xref ref-type="bibr" rid="article-18639.r2">[2]</xref><xref ref-type="bibr" rid="article-18639.r3">[3]</xref>&#x000a0;Bronchiectasis is responsible for the&#x000a0;significant loss of lung function and one that can result in considerable morbidity and even early mortality.</p>
      </sec>
      <sec id="article-18639.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Historically, the most common cause of bronchiectasis was thought to be an antecedent respiratory infection, often during childhood. The causes are idiopathic, acquired, or infection-related.</p>
        <p>Bacterial Infections</p>
        <list list-type="bullet">
          <list-item>
            <p>Mycobacterium: Tuberculosis and atypical</p>
          </list-item>
          <list-item>
            <p>Haemophilus influenzae</p>
          </list-item>
          <list-item>
            <p>Pseudomonas aeruginosa</p>
          </list-item>
          <list-item>
            <p>Staphylococcus aureus</p>
          </list-item>
          <list-item>
            <p>Mycoplasma and HIV</p>
          </list-item>
        </list>
        <p>Viral Infections</p>
        <list list-type="bullet">
          <list-item>
            <p>Respiratory syncytial virus and measles</p>
          </list-item>
        </list>
        <p>Fungal Infections</p>
        <p>Bronchial obstruction</p>
        <list list-type="bullet">
          <list-item>
            <p>Foreign body</p>
          </list-item>
          <list-item>
            <p>Mucus plug</p>
          </list-item>
          <list-item>
            <p>Tumors</p>
          </list-item>
          <list-item>
            <p>Hilar lymphadenopathy (right middle lobe syndrome: extrinsic compression from postinfectious adenopathy)</p>
          </list-item>
        </list>
        <p>Postinflammatory pneumonitis</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic aspiration/gastroesophageal reflux disorder</p>
          </list-item>
          <list-item>
            <p>Chronic sinusitis</p>
          </list-item>
          <list-item>
            <p>Inhalational injury</p>
          </list-item>
        </list>
        <p>Congenital/Genetic</p>
        <list list-type="bullet">
          <list-item>
            <p>Cystic fibrosis</p>
          </list-item>
          <list-item>
            <p>Young syndrome</p>
          </list-item>
          <list-item>
            <p>PCD: primary ciliary dyskinesia (Kartenger Syndrome)</p>
          </list-item>
          <list-item>
            <p>immunodeficiency (hypogammaglobulinemia)</p>
          </list-item>
          <list-item>
            <p>Alpha1-antitrypsin deficiency (AAT)</p>
          </list-item>
          <list-item>
            <p>Mounier-Kuhn syndrome</p>
          </list-item>
        </list>
        <p>Inflammatory diseases</p>
        <list list-type="bullet">
          <list-item>
            <p>Ulcerative colitis</p>
          </list-item>
          <list-item>
            <p>Rheumatoid arthritis</p>
          </list-item>
          <list-item>
            <p>Sj&#x000f6;gren syndrome</p>
          </list-item>
        </list>
        <p>Pulmonary Diseases</p>
        <list list-type="bullet">
          <list-item>
            <p>Asthma&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Bronchomalacia</p>
          </list-item>
          <list-item>
            <p>Cronic-obstructive pulmonary disease (COPD) (reported in up to 50% of patients with moderate-to-severe COPD)</p>
          </list-item>
          <list-item>
            <p>Diffuse panbronchiolitis</p>
          </list-item>
          <list-item>
            <p>Idiopathic pulmonary fibrosis (traction bronchiectasis)</p>
          </list-item>
        </list>
        <p>Altered immune response</p>
        <list list-type="bullet">
          <list-item>
            <p>Allergic Bronchopulmonary Aspergillosis</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity pneumonitis</p>
          </list-item>
        </list>
        <p>Others</p>
        <list list-type="bullet">
          <list-item>
            <p>Yellow nail syndrome (yellow nails, lymphedema, pleural effusion, bronchiectasis 40% first described in 1964)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18639.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Bronchiectasis predominance is not clearly understood. Global statistics suggest that the incidence of bronchiectasis has risen over the past few years. It can exist in any age group. However, it generally occurred in childhood during the pre-antibiotic period.<xref ref-type="bibr" rid="article-18639.r4">[4]</xref> Recent evidence shows that bronchiectasis disproportionately affects women and older individuals, and may be contributing to an increasing healthcare burden.</p>
      </sec>
      <sec id="article-18639.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The three most important mechanisms that contribute to the pathogenesis of bronchiectasis are recurrent infections, airway obstruction, and peribronchial fibrosis.</p>
        <p>Neutrophils dominate airway inflammation in bronchiectasis, driven by high concentrations of neutrophil chemoattractants such as interleukin-8 (CXCL-8), and leukotriene B4. Airway bacterial colonization occurs because of impaired mucociliary clearance and because of the failure of neutrophil opsonophagocytic killing. Other mechanisms of immune dysfunction include the inability to clear apoptotic cells and invasion of T-cells, with recent reports leading to Th17 cells playing a significant role. Histologic changes in bronchiectasis include cartilage destruction and fibrosis, mucosal and mucous gland hyperplasia, inflammatory cell infiltration, and increased mucous and exudate.</p>
      </sec>
      <sec id="article-18639.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>History of a long-standing cough with purulence is typical of bronchiectasis. Patients may report repetitive pulmonary infections that require antibiotics over several years. Patients can also present with progressive dyspnea, intermittent wheezing, hemoptysis, pleuritic chest pain, and associated fatigue and weight loss.&#x000a0;The hemoptysis&#x000a0;is mild and manifested by blood flecks in the patient's usual purulent sputum, which is&#x000a0;occasionally life-threatening. Often patients are diagnosed after many years of symptoms when a chronic cough or hemoptysis becomes debilitating.</p>
        <p>Cough: 98%, sputum: 78% (sputum is typically mucoid and relatively odorless), dyspnea: 62%, haemoptysis: 56% to 92%, and pleuritic chest pain: 20% (secondary to chronic coughing).</p>
        <p><bold>Physical:</bold> Findings are nonspecific.</p>
        <p><bold>General findings</bold> may include digital clubbing (2% to 3%), cyanosis, plethora, wasting, and weight loss.</p>
        <list list-type="bullet">
          <list-item>
            <p>Local chest examination:&#x000a0; Most commonly crackles and wheezes on auscultation.</p>
          </list-item>
          <list-item>
            <p>Crackles: 75%, usually bi-basal.</p>
          </list-item>
          <list-item>
            <p>Wheezing: 22% (wheezing may be due to airflow obstruction from secretions)</p>
          </list-item>
        </list>
        <p>
<bold>Clinical Features of Associated Causative condition:&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Connective tissue diseases: Arthritis Sicca syndrome</p>
          </list-item>
          <list-item>
            <p>ABPA: Prominent wheezing</p>
          </list-item>
          <list-item>
            <p>Bronchial obstruction: localized wheezing</p>
          </list-item>
          <list-item>
            <p>PCD, CF, Young Syndrome: Recurrent sinus disease, infertility</p>
          </list-item>
          <list-item>
            <p>Features&#x000a0;of acute exacerbation of bronchiectasis: Change in sputum production, increased dyspnea, increased cough, fever, increased wheezing, and reduced pulmonary function.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18639.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The recommendations of the British Thoracic Society (BTS) suggest checking for underlying factors involving immunoglobulin tests (IgA, IgM, IgG, and IgE), and testing to exclude ABPA (specific IgE to Aspergillus, IgG to Aspergillus, and eosinophil count).<xref ref-type="bibr" rid="article-18639.r5">[5]</xref><xref ref-type="bibr" rid="article-18639.r6">[6]</xref><xref ref-type="bibr" rid="article-18639.r7">[7]</xref><xref ref-type="bibr" rid="article-18639.r8">[8]</xref> Sputum culture to exclude&#x000a0;nontuberculous mycobacteria (NTM) and assessment of autoantibodies are also suggested. Testing for cystic fibrosis (CF) (sweat test and/or screening for common CF mutations) is recommended for patients aged younger than 40 years or with recurrent <italic toggle="yes">Pseudomonas aeruginosa&#x000a0;</italic>and <italic toggle="yes">Staphylococcus aureus</italic> isolation, or upper lobe predominant disease irrespective of age.</p>
        <p>Alpha-1 Antitrypsin level, Ciliary function analysis, and Serology for HIV&#x000a0;&#x000a0;if indicated.</p>
        <p>
<bold>Imaging:&#x000a0;</bold>
</p>
        <p><bold>Chest radiography</bold>&#x000a0;is usually the initial study performed in&#x000a0;suspected bronchiectasis.</p>
        <p>Signs on chest x-ray include the identification of parallel linear densities, tram-track opacities, or ring shadows reflecting thickened and abnormally dilated bronchial walls.</p>
        <p>Signs of complications/exacerbations, such as patchy densities due to mucoid impaction (mucus may become of high density due to chronic inspissation)&#x000a0;and consolidation, volume loss secondary to mucoid bronchial obstruction or chronic cicatrization are also seen.</p>
        <p>In comparison to&#x000a0;chest x-ray, CT is both more sensitive and provides more specific information. In addition to making the diagnosis, the pattern of disease on HRCT may enable one to limit the differential to a single/few specific causative entities.</p>
        <p>The <bold>CT chest</bold> signs of bronchiectasis were first described by NAIDICH et al. in 1982.&#x000a0;Multidetector computed tomography (MDCT) is preferred over high-resolution computed tomography (HRCT) as it can obtain thin sections of 1 mm (high resolution). HRCT is performed when MDCT is not available.</p>
        <p>Bronchial dilation, the cardinal sign of bronchiectasis, is characterized:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>A&#x000a0;broncho arterial ratio (BAR) of more than 1</p>
          </list-item>
          <list-item>
            <p>Lack of bronchial tapering (normal airways diminish in caliber as they extend toward the lung periphery)</p>
          </list-item>
          <list-item>
            <p>Visibility of airways within 1 cm of the pleural surface (normal airways should not be visualized this far out in the lung periphery)&#x000a0;or abutting the mediastinal pleural surface.</p>
          </list-item>
        </list>
        <p>
<bold>Usual Pattern on CT scan of the Chest</bold>
</p>
        <p><italic toggle="yes">Cylindrical (tram track sign):</italic><bold>&#x000a0;</bold>Dilated airways seen in a horizontal orientation.</p>
        <p><italic toggle="yes">Signet-ring:&#x000a0;</italic>The dilated airway lies adjacent to a pulmonary artery branch giving the appearance of a ring (internal bronchial diameter greater than that of the adjacent pulmonary artery).</p>
        <p><italic toggle="yes">Varicose:</italic><bold>&#x000a0;</bold>Implies non-uniform bronchial dilatation. The bronchi resemble varicose veins. The luminal dilatation is characterized by alternating areas of luminal dilatation and constriction, creating a beaded appearance, and the wall thickening is irregular. This varicose bronchiectasis serves as an intermediate step before the development of grossly dilated cystic airways.</p>
        <p><italic toggle="yes">Cystic or saccular:</italic> A cluster of thin-walled cystic spaces.</p>
        <p><italic toggle="yes">Mosaic lung attenuation: </italic>The terminology is used to characterize heterogeneous lung density in the damaged lung segments owing to air trapping and hence has a geographic distribution. On expiration, this result can be produced or exaggerated.</p>
        <p><italic toggle="yes">Dilated bronchial arteries:</italic>&#x000a0;These are best-demonstrated post administration of intravenous contrast. These tortuous vessels extend along the central airways toward the hila. It is these vessels that are often responsible for hemoptysis.</p>
        <p>
<bold>Other Findings:</bold>
</p>
        <p>
<italic toggle="yes">Lobar collapse</italic>
</p>
        <p><italic toggle="yes">Mycetoma formation</italic> (Fungus ball): Aspergillus fumigatus (a fungus) may colonize dilated airways or bullae/cavities. It is a major source of hemoptysis.</p>
        <p>
<italic toggle="yes">Decreased Lung function:</italic>
</p>
        <p>Airflow obstruction: FEV1 decreased</p>
        <p>Air trapping: Residual volume increased</p>
      </sec>
      <sec id="article-18639.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Bronchiectasis is treatable but rarely curable.</p>
        <p>
<bold>Treatment Goals:</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Identifying and treating the underlying cause</p>
          </list-item>
          <list-item>
            <p>Improve tracheobronchial clearance</p>
          </list-item>
          <list-item>
            <p>Control infection</p>
          </list-item>
          <list-item>
            <p>Reverse airflow obstruction</p>
          </list-item>
        </list>
        <p>
<bold>General Management</bold>
</p>
        <p><bold>1. Identifying and treating the underlying cause:</bold>&#x000a0;Immunoglobulin replacement, steroids, antifungals for ABPA, treatment for NTM, and CF all represent opportunities to treat the underlying cause specifically, and systematic testing of all patients is recommended in consensus guidelines.<xref ref-type="bibr" rid="article-18639.r9">[9]</xref><xref ref-type="bibr" rid="article-18639.r10">[10]</xref><xref ref-type="bibr" rid="article-18639.r11">[11]</xref></p>
        <p><bold>2. Improve tracheobronchial clearance:&#x000a0;</bold>Most physicians recommend mucus clearance as the mainstay of therapy in bronchiectasis, Postural drainage consists of adopting a position in which the uppermost lobe is drained, and should be performed for a minimum of 5 to 10 minutes twice a day. Efficiently performed, this is of great value both in reducing the amount of cough and sputum and in preventing recurrent episodes of bronchopulmonary infection.</p>
        <p>Deep breathing followed by forced expiratory maneuvers (the "active cycle of breathing" technique) is of help in allowing secretions in the dilated bronchi to gravitate towards the trachea, from which vigorous coughing can clear them. "Percussion" of the chest wall with cupped hands may help to dislodge sputum<italic toggle="yes">,</italic> and a number of mechanical devices are available, which cause the chest wall to oscillate, thus achieving the same effect.</p>
        <p><bold>3. Control infection</bold>: The choice of antibiotic should primarily be based on the results of culture and sensitivity. When no specific pathogen is identified, and the patient is not seriously ill, an oral agent like amoxicillin, co-amoxiclav, or macrolides for 2 weeks is sufficient.</p>
        <p>Use a&#x000a0;higher dose of oral amoxicillin 1 gm twice per day for 2 weeks, especially if colonized with <italic toggle="yes">H. influenza.</italic> If pseudomonas-colonized, then a 2-week course of ciprofloxacin 750 mg twice per day (with cautious use in the elderly) is reasonable.</p>
        <p>For patients with moderate-to-severe symptoms, parenteral antibiotics, such as an aminoglycoside (gentamicin, tobramycin), antipseudomonal synthetic penicillin, a third-generation cephalosporin, or a fluoroquinolone, may be indicated.</p>
        <p>Treatment for Pseudomonas isolates&#x000a0;2 weeks of intravenous (IV) antipseudomonal antibiotics, nebulized colistin for 3 months, or nebulized colistin for 3 months with an additional 4 weeks of oral ciprofloxacin.</p>
        <p>Maintenance therapy with intermittent antibiotics is not used routinely in patients with non-CF bronchiectasis, and the decision to use long-term antibiotics should be individualized.</p>
        <p>Inhaled aminoglycosides can be of benefit in chronic non-CF bronchiectasis; however, the treatment needs to be of sustained duration.</p>
        <p><bold>4. Control reverse airflow obstruction</bold>: In patients with airflow obstruction, inhaled bronchodilators and corticosteroids should be used to enhance airway patency.</p>
        <p><bold>5. Lifestyle modifications</bold>:&#x000a0;As with other respiratory diseases, patients with bronchiectasis should be encouraged to stop smoking. Vaccination against influenza and pneumococcal disease is also recommended.</p>
        <p>
<bold>Adjunctive Surgical Treatment:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Surgery is only indicated in a small proportion of cases. These are usually young patients in whom the bronchiectasis is unilateral and confined to a single lobe or segment, as demonstrated by CT.</p>
          </list-item>
          <list-item>
            <p>Surgery is an important adjunct to therapy in some patients with advanced or complicated disease.</p>
          </list-item>
          <list-item>
            <p>Single- or double-lung transplantation has been used as a treatment of severe bronchiectasis, predominantly when related to CF. In general, consider patients with CF and bronchiectasis for lung transplantation when FEV falls below 30% of the predicted value. Female patients and younger patients may need to be considered sooner.</p>
          </list-item>
          <list-item>
            <p>Massive hemoptysis: Bronchial artery embolization and/or surgery is first-line therapy for the management of massive hemoptysis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18639.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Alpha 1 antitrypsin deficiency</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Aspiration pneumonitis and pneumonia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Asthma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bronchitis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chronic obstructive pulmonary lung disease</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cystic Fibrosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Emphysema</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Gastroesophageal reflux disease</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tuberculosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18639.s10" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Bronchiectasis complications include pneumonia, lung abscess, empyema, septicemia, cor pulmonale, respiratory failure, secondary amyloidosis with nephrotic syndrome, and recurrent pleurisy.</p>
        <p>
<bold>Prognosis</bold>
</p>
        <p>The disease is progressive when associated with ciliary dysfunction and cystic fibrosis, and eventually causes respiratory failure in other patients. The prognosis can be relatively good if postural drainage is performed regularly, and antibiotics are used judiciously.</p>
      </sec>
      <sec id="article-18639.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Bronchiectasis is a progressive disorder with no cure. Hence it is best managed by an interprofessional team that includes the primary care physician, nurse practitioner, pulmonologist, infectious disease expert, thoracic surgery, and an internist. The key is to improve symptoms and prevent relapses.<xref ref-type="bibr" rid="article-18639.r12">[12]</xref><xref ref-type="bibr" rid="article-18639.r13">[13]</xref> These patients often develop respiratory infections that require antibiotics. At some point, most patients develop complications that include pneumonia, lung abscess, empyema, septicemia, cor pulmonale, respiratory failure, secondary amyloidosis with nephrotic syndrome, and recurrent pleurisy.</p>
        <p>The disease is progressive when associated with ciliary dysfunction and cystic fibrosis and eventually causes respiratory failure. In other patients, the prognosis can be relatively good if postural drainage is performed regularly, and antibiotics are used judiciously.<xref ref-type="bibr" rid="article-18639.r7">[7]</xref></p>
      </sec>
      <sec id="article-18639.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18639&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18639">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/lung-disease-respiratory-health/bronchiectasis-lung-inflammation/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=18639">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18639/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18639">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-18639.s13">
        <fig id="article-18639.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Allergic Bronchopulmonary Aspergillosis on CT Scan. Computed tomography (CT) images reveal bronchiectasis in both upper lobes of a patient with bronchial asthma, indicative of allergic bronchopulmonary aspergillosis. Contributed by M Salahuddin, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ABPA." position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-18639.s14">
        <title>References</title>
        <ref id="article-18639.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ho</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cusack</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Chaudhary</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Satia</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kurmi</surname>
                <given-names>OP</given-names>
              </name>
            </person-group>
            <article-title>Under- and over-diagnosis of COPD: a global perspective.</article-title>
            <source>Breathe (Sheff)</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-35</page-range>
            <pub-id pub-id-type="pmid">30838057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18639.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Crimi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Heffler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Campisi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Noto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Crimi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Vitamin D and disease severity in bronchiectasis.</article-title>
            <source>Respir Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>148</volume>
            <fpage>1</fpage>
            <page-range>1-5</page-range>
            <pub-id pub-id-type="pmid">30827468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18639.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guan</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>XR</given-names>
              </name>
              <name>
                <surname>de la Rosa-Carrillo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Martinez-Garcia</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>The significant global economic burden of bronchiectasis: a pending matter.</article-title>
            <source>Eur Respir J</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>53</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">30819807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18639.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goeminne</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Diel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Filonenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Juelich</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Upton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wichmann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chalmers</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>The economic burden of bronchiectasis - known and unknown: a systematic review.</article-title>
            <source>BMC Pulm Med</source>
            <year>2019</year>
            <month>Feb</month>
            <day>28</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <pub-id pub-id-type="pmid">30819166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18639.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schoovaerts</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lorent</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Goeminne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aliberti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dupont</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>National Survey on the Management of Adult Bronchiectasis in Belgium.</article-title>
            <source>COPD</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-74</page-range>
            <pub-id pub-id-type="pmid">30786778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18639.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Neill</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Airway clearance, mucoactive therapies and pulmonary rehabilitation in bronchiectasis.</article-title>
            <source>Respirology</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>227</fpage>
            <page-range>227-237</page-range>
            <pub-id pub-id-type="pmid">30650472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18639.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cairn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Loebinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Man</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary rehabilitation in bronchiectasis: a propensity-matched study.</article-title>
            <source>Eur Respir J</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>53</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">30578381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18639.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kocurek</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Jagana</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Noncystic fibrosis bronchiectasis management: opportunities and challenges.</article-title>
            <source>Curr Opin Pulm Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>192</fpage>
            <page-range>192-200</page-range>
            <pub-id pub-id-type="pmid">30640187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18639.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bell</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Elborn</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Byrnes</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Bronchiectasis: Treatment decisions for pulmonary exacerbations and their prevention.</article-title>
            <source>Respirology</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>11</issue>
            <fpage>1006</fpage>
            <page-range>1006-1022</page-range>
            <pub-id pub-id-type="pmid">30207018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18639.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitchelmore</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hettle</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Risk of Bacterial Transmission in Bronchiectasis Outpatient Clinics.</article-title>
            <source>Curr Pulmonol Rep</source>
            <year>2018</year>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>72</fpage>
            <page-range>72-78</page-range>
            <pub-id pub-id-type="pmid">30148050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18639.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Visser</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Bye</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Management of bronchiectasis in adults.</article-title>
            <source>Med J Aust</source>
            <year>2018</year>
            <month>Aug</month>
            <day>20</day>
            <volume>209</volume>
            <issue>4</issue>
            <fpage>177</fpage>
            <page-range>177-183</page-range>
            <pub-id pub-id-type="pmid">30107772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18639.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalrymple</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kenia</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia: a guideline review.</article-title>
            <source>Arch Dis Child Educ Pract Ed</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>104</volume>
            <issue>5</issue>
            <fpage>265</fpage>
            <page-range>265-269</page-range>
            <pub-id pub-id-type="pmid">30076157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18639.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Polverino</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dimakou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hurst</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Martinez-Garcia</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Miravitlles</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paggiaro</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shteinberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aliberti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chalmers</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions.</article-title>
            <source>Eur Respir J</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>52</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">30049739</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
